Opendata, web and dolomites

KIT

Kidney Injury Technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 KIT project word cloud

Explore the words cloud of the KIT project. It provides you a very rough idea of what is the project "KIT" about.

people    envisioned    deadly    gold    royalties    international    critical    price    128    rate    started    annual       sought    650       clinical       standard    capacity    acquire    sales    clinically    human    revolutionary    companies    sme    initially    manufacturing    inren    expenditure    upfront    dismally    poses    license    maturity    reference    posing       validation    prototype    economic    prognosis    vitro    handling    smes    acute    global    2023    yearly    tests    health    thorough    yield    channels    incident    gt    regulated    renal    income    transferability    huge    biomarker    2017    transfer    35    thereafter    2018    disease    grows    technological    company    aki    samples    patented    69    elevated    patient    instrument    unitary    bio    marker    10    consolidation    market    elisa    diagnostics    competitors    reduce    billion    diagnostic    laid    kit    population    worldwide    commercialization    penetration    incidence    sale    ivd   

Project "KIT" data sheet

The following table provides information about the project.

Coordinator
BIO-INREN SL 

Organization address
address: NORBERTO CUESTA DUTARI 39 4 D
city: SALAMANCA
postcode: 37007
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.bio-inren.es
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2015-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIO-INREN SL ES (SALAMANCA) coordinator 50˙000.00

Map

 Project objective

Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and economic problem worldwide. Bio-inRen’s diagnostic system is envisioned to 1) change the concept and approach to AKI clinical handling, 2) become a reference diagnostic, 3) reduce AKI incidence (by 2.5-5% initially) and improve patient prognosis, and 4) reduce the elevated cost associated to AKI (1% of their global health expenditure, which will be reduced initially in 650 M € in this 1.35 billion people population). An ELISA-based, clinically useful prototype kit has been developed for measurement of human samples. Clinical validation has started, although Bio-inRen’s system needs thorough clinical validation to acquire technological maturity and transferability, for which Phase I and II SME instrument are necessary, on which all the company’s resources will be laid. As a new concept, Bio-inRen’s technology has no competitors in the market or under development. The In Vitro Diagnostic Market grows at a 7% annual rate and will reach $69.1 billion by 2017. AKI-specific market is estimated at 3.5 M cases and 70 M diagnostic tests of the existing gold standard marker. Because Diagnostics is a global and regulated market, Bio-inRen will license the system to large companies and SMEs in the IVD market with manufacturing capacity and international commercialization channels. Technology transfer is expected by 2018 to yield 1 M € upfront and 5% royalties on sales thereafter. 5% market penetration is sought by 2023. As of today, 5% of 70 M tests poses 3.5 M tests as Bio-inRen’s market (6.4 M tests by 2023 at 7% annual growth rate). At a unitary sale price of 20 €/test, this means 128 M €. 5% royalties will produce a yearly income of 6.4 M € to Bio-inRen, which are critical for the consolidation and growth of the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More